Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 03, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 625,000 ordinary shares of 25 pence each.
- Purchase Date: May 03, 2007.
- Purchase Price: 1,441.02 pence per share.
- Treasury Shares Held: 291,432,678 shares (post-purchase).
- Shares in Issue: 5,727,964,469 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 625,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 291,432,678. The number of shares in issue, representing total voting rights, stands at 5,727,964,469.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,727,964,469) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (291,432,678) for capital structure analysis.
- Review the purchase price of 1,441.02 pence per share against market prices on May 03, 2007.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial metrics.